• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hepatic - Colorectal Metastasis - Pipeline Review, H2 2012 Product Image

Hepatic - Colorectal Metastasis - Pipeline Review, H2 2012

  • Published: November 2012
  • 44 pages
  • Global Markets Direct

Hepatic - Colorectal Metastasis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hepatic - Colorectal Metastasis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hepatic - Colorectal Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic - Colorectal Metastasis. Hepatic - Colorectal Metastasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatic - Colorectal Metastasis.
- A review of the Hepatic READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Hepatic - Colorectal Metastasis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hepatic - Colorectal Metastasis 7
Hepatic - Colorectal Metastasis Therapeutics under Development by Companies 9
Hepatic - Colorectal Metastasis Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Hepatic - Colorectal Metastasis Therapeutics – Products under Development by Companies 13
Hepatic - Colorectal Metastasis Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Hepatic - Colorectal Metastasis Therapeutics Development 15
Celsion Corporation 15
Amgen Inc. 16
Hepatic - Colorectal Metastasis – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
Adecatumumab - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
doxorubicin - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Floxuridine + Fluorouracil + Radiofrequency Ablation - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Adecatumumab + FOLFOX - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
ALF-5755 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Avastin + Radiation Therapy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Xelox + Bevacizumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Bevacizumab + Capecitabine + Irinotecan + Oxaliplatin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Hepatic - Colorectal Metastasis Therapeutics – Drug Profile Updates 36
Hepatic - Colorectal Metastasis Therapeutics – Discontinued Products 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products Under Development for Hepatic - Colorectal Metastasis, H2 2012 7
Products under Development for Hepatic - Colorectal Metastasis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Celsion Corporation, H2 2012 15
Amgen Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Hepatic - Colorectal Metastasis Therapeutics – Drug Profile Updates 36
Hepatic - Colorectal Metastasis Therapeutics – Discontinued Products 42

List of Figures
Number of Products under Development for Hepatic - Colorectal Metastasis, H2 2012 7
Products under Development for Hepatic - Colorectal Metastasis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos